23 January 2026
Executive Summary
A global vaccine partnership has been established between SK bioscience, MSD (Merck & Co.), and the Hilleman Laboratories to enhance the manufacturing capacity and global supply of vaccines targeting Zaire ebolavirus. Supported by the Coalition for Epidemic Preparedness Innovations (CEPI), the collaboration underscores a renewed focus on pandemic readiness, resilient vaccine manufacturing, and equitable access for high-risk regions.
Strategic Rationale: From Innovation to Sustainable Supply
While effective Ebola vaccines already exist, ensuring reliable, scalable, and rapid supply remains a critical global health challenge. The partnership is designed to move beyond episodic outbreak response toward a standing manufacturing and supply infrastructure capable of responding to future flare-ups.
Key objectives include:
- Expanding global manufacturing capacity for Ebola vaccines
- Strengthening technology transfer and production readiness
- Reducing lead times between outbreak detection and vaccine deployment
Complementary Strengths Across the Partnership
The collaboration brings together distinct but complementary capabilities:
- SK bioscience contributes large-scale vaccine manufacturing expertise and global supply experience
- MSD provides deep scientific, regulatory, and clinical development capabilities in infectious diseases
- Hilleman Laboratories supports process development and cost-efficient manufacturing for global access
With CEPI’s backing, the partnership aligns public funding with private-sector execution to address market gaps that traditional commercial models often overlook.
CEPI’s Role: Anchoring Global Health Security
CEPI’s support reflects its mandate to ensure vaccines against epidemic-prone diseases are not only developed, but also manufactured and stockpiled sustainably. By enabling long-term capacity rather than one-off production, CEPI aims to strengthen the global system’s ability to respond swiftly to emerging threats.
A Broader Signal: Manufacturing Readiness as a Strategic Priority
The initiative highlights a broader shift in global health strategy:
- From reactive vaccine production
- To proactive manufacturing preparedness
As geopolitical risk, climate change, and population mobility increase outbreak frequency, manufacturing resilience is becoming as critical as scientific discovery.
Implications for Global Vaccine Ecosystems
- Governments and global health agencies gain more predictable access to critical vaccines
- Manufacturers benefit from sustained demand signals and shared risk
- At-risk regions see improved access to life-saving countermeasures
The model may serve as a template for future partnerships targeting other high-threat pathogens.
Outlook: Building the Backbone of Outbreak Response
By reinforcing manufacturing and supply chains for Ebola vaccines, the SK bioscience–MSD–Hilleman partnership represents a step toward institutionalizing epidemic preparedness rather than treating it as an emergency exception.
The strategic question ahead:
Can sustained public–private vaccine partnerships turn outbreak readiness into permanent global infrastructure?
By